Eric Santiago, MD
Internal Medicine · Fpo, APNPI 1457502114
Payments from drug & device makers
Across 696 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- AbbVie$1K
- Boehringer Ingelheim$809
- Lilly USA, LLC$792
- Pfizer$694
- plus $4K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 107 | $1,717 |
| AstraZeneca | 74 | $1,245 |
| AbbVie(2 entities) | 115 | $1,126 |
| Boehringer Ingelheim | 51 | $809 |
| Lilly USA, LLC | 51 | $792 |
| Pfizer | 44 | $694 |
| GSK | 39 | $613 |
| Amgen | 38 | $594 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $493 |
| Novartis | 22 | $405 |
| Bayer | 19 | $353 |
| Merck | 16 | $261 |
| Abbott | 13 | $245 |
| Sumitomo Pharma America, Inc. | 12 | $195 |
| Biohaven Pharmaceuticals, Inc. | 9 | $145 |
| Johnson & Johnson | 8 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $124 |
| Sanofi-aventis U.S. LLC | 8 | $115 |
| Esperion Therapeutics, Inc. | 5 | $98 |
| Exact Sciences | 5 | $94 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $79 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| Amarin Pharma, Inc. | 2 | $45 |
| Dexcom, Inc. | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Genentech USA, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Vertex | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $14 |
How this compares
Too few internal medicine providers in APto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Fpo
- Matthew FowlerFpo$135
- John GilstadFpo$0
- Xin WeiApo$768
- Cynthia ShimApo$489
- Jacob BesslerAndersen Afb Apo$291
- Timothy GockeApo$178
- Richard PaulApo$134
- Joe ZhangApo$131
- Luke RinesApo$48
- Danielle PresleyApo$47
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.